Modulation and Long-term Release of Cardiac Fibroblast Secretome to Enhance Cardiac Cell Survival under Hypoxia by ZHAI, JIN
Washington University in St. Louis 
Washington University Open Scholarship 
Engineering and Applied Science Theses & 
Dissertations McKelvey School of Engineering 
Spring 5-2021 
Modulation and Long-term Release of Cardiac Fibroblast 
Secretome to Enhance Cardiac Cell Survival under Hypoxia 
JIN ZHAI 
Washington University in St. Louis 
Follow this and additional works at: https://openscholarship.wustl.edu/eng_etds 
 Part of the Engineering Commons 
Recommended Citation 
ZHAI, JIN, "Modulation and Long-term Release of Cardiac Fibroblast Secretome to Enhance Cardiac Cell 
Survival under Hypoxia" (2021). Engineering and Applied Science Theses & Dissertations. 570. 
https://openscholarship.wustl.edu/eng_etds/570 
This Thesis is brought to you for free and open access by the McKelvey School of Engineering at Washington 
University Open Scholarship. It has been accepted for inclusion in Engineering and Applied Science Theses & 
Dissertations by an authorized administrator of Washington University Open Scholarship. For more information, 
please contact digital@wumail.wustl.edu. 
Washington University in St. Louis 
McKelvey School of Engineering 
Department of Biomedical Engineering 
 






Modulation and Long-term Release of Cardiac Fibroblast Secretome to Enhance Cardiac Cell 




A thesis presented to the McKelvey School of Engineering of Washington University in St. 




St. Louis, Missouri 
  
 











Table of Contents 
List of Tables .................................................................................................................................. iv 
List of Figures .................................................................................................................................. v 
Acknowledgements ........................................................................................................................ vi 
Abstract ......................................................................................................................................... vii 
Chapter 1 Introduction ..................................................................................................................... 1 
1.1 Myocardial infarction .............................................................................................. 1 
1.2 Stem cell therapy to treat MI ................................................................................... 1 
1.3 Cell secretome ......................................................................................................... 2 
1.4 Delivery system for cell secretome ......................................................................... 3 
Chapter 2 Modulation of Cardiac Fibroblast Secretome in Response to Different Environmental 
Cues ................................................................................................................................................. 4 
2.1 Introduction ............................................................................................................. 4 
2.2 Materials and methods ............................................................................................. 4 
2.2.1 Materials ......................................................................................................... 4 
2.2.2 RCF culture .................................................................................................... 5 
2.2.3 PAM gel fabrication and characterization ...................................................... 5 
2.2.4 Collagen coating of PAM gels ....................................................................... 6 
2.2.5 Immunocytochemical staining ........................................................................ 6 
2.2.6 RCF secretome collection ............................................................................... 7 
2.2.7 mRNA collection and concentration measurement ........................................ 7 
2.2.8 cDNA synthesis .............................................................................................. 8 
2.2.9 Real-time RT-PCR ......................................................................................... 8 
 ii 
2.2.10 Sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE)
 ................................................................................................................................. 8 
2.2.11 Enzyme-linked immunosorbent assay (ELISA) ........................................... 9 
2.2.12 HUVEC culture ............................................................................................ 9 
2.2.13 HUVEC survival (MTT assay) ................................................................... 10 
2.2.14 HUVEC migration ...................................................................................... 11 
2.2.15 HUVEC tube formation .............................................................................. 11 
2.2.16 Cardiomyocyte culture ............................................................................... 12 
2.2.17 Cardiomyocyte survival (MTT assay) ........................................................ 12 
2.2.18 Statistical analysis ...................................................................................... 12 
2.3 Results and Discussion .......................................................................................... 13 
2.3.1 Gene expression of RCF secretome in response to oxygen content ............. 13 
2.3.2 PAM Gel Fabrication and Characterization ................................................. 14 
2.3.3 Effects of PAM gels on RCF secretome under hypoxic condition .............. 15 
2.3.4 Effects of RCF secretome on HUVEC survival, migration and tube formation under 
hypoxic condition .................................................................................................. 16 
2.3.5 Effect of RCF secretome on cardiomyocytes survival under hypoxic condition
 ............................................................................................................................... 18 
2.4 Conclusion ............................................................................................................. 18 
Chapter 3 Targeted Delivery of Platelet Membrane Coated PLGA Nanoparticles with Sustained 
Cardiac Fibroblast Secretome Release .......................................................................................... 19 
3.1 Intro ....................................................................................................................... 19 
3.2 Materials and methods ........................................................................................... 19 
 iii 
3.2.1 Materials ....................................................................................................... 19 
3.2.2 Secretome collection .................................................................................... 19 
3.2.3 Nanoparticle fabrication and characterization .............................................. 20 
3.2.4 Growth factor release characterization ......................................................... 20 
3.2.5 Platelet membrane coating and characterization .......................................... 21 
3.2.6 Cell uptake .................................................................................................... 22 
3.2.6 Statistical analysis ........................................................................................ 23 
3.3 Results and Discussion .......................................................................................... 23 
3.3.1 Fabrication and characterization of PLGA nanoparticles ............................. 23 
3.3.2 Growth factor release kinetics ...................................................................... 23 
3.3.3 Cell uptake for platelet membrane coated nanoparticles .............................. 24 
3.4 Conclusion ............................................................................................................. 24 
Chapter 4 Future Work .................................................................................................................. 25 









List of Tables 
Table 1. Concentration of acrylamide and bis-acrylamide of PAM gels. ..................................... 26 
Table 2. Primer sequences used in real-time RT-PCR. ................................................................. 26 
Table 3. PAM gel stiffness measured by rheology. ....................................................................... 27 





List of Figures 
Figure 1. Gene expression of VEGF, IL1β, and TGFβ in RCF under 1% O2, 5% O2, and 21% O2 
culture conditions.  ........................................................................................................................ 28 
Figure 2. Fabricated PAM gel and stiffness of PAM gels as measured by rheometer. ................. 28 
Figure 3. Immunocytochemical staining of F-actin (green) and α-SMA (red) of RCF cultured on 
PAM1 to 4 and culture plate. . ....................................................................................................... 29 
Figure 4. Protein expression of RCF cultured on PAM1 to 4 gels. ............................................... 29 
Figure 5. Gene expression of RCF cultured on PAM1 to 4 .......................................................... 30 
Figure 6. Concentration of bFGF of RCF secretome collected on PAM1 to 3 ............................. 30 
Figure 7. In vitro HUVEC survival under hypoxic condition ....................................................... 31 
Figure 8. In vitro HUVEC migration under hypoxic condition .................................................... 31 
Figure 9. In vitro HUVEC tube formation under hypoxic condition with quantification ............. 32 
Figure 10. In vitro cardiomyocytes survival under hypoxic condition ......................................... 32 
Figure 11. DLS of uncoated and PLM-coated nanoparticles and stability of uncoated 
nanoparticles. ................................................................................................................................. 33 
Figure 12. Growth factor release kinetics ...................................................................................... 33 





I would like to express my sincere thanks to my research advisor Dr. Jianjun Guan. Without his 
introduction and suggestion, I can’t have the precious opportunity to join in the lab and do the 
project. I’d like to specially thank Ya Guan for helping me and giving me many suggestions and 
advice during the project. I’d like to thank the members in the lab. It is your effort that help me to 
achieve goals.  
I’d like to thank my mother Huiling Lu and my father Guiyuan Zhai. Only with your support can 





















Modulation and Long-term Release of Cardiac Fibroblast Secretome to Enhance Cardiac Cell 
Survival under Hypoxia 
By 
Jin Zhai 
Master of Science in Biomedical Engineering 
Washington University in St. Louis, 2021 
Professor Jianjun Guan 
The irreversible damage to the heart caused by myocardial infarction (MI) leads to over one million 
deaths in the United States every year. There are several approaches to treat MI, such as 
angioplasty, redirected blood flow, and electrical medical devices, but they cannot promote new 
cardiac tissue generation, thus leading to potential high risk of re-surgeries. To overcome this 
limitation, stem cell therapy is regarded as a promising method. However, the implantation of stem 
cells has ethical and safe concern and the efficiency is limited due to low cell engraftment. 
Moreover, the effect of stem cell is predominantly attributed to paracrine effect. Therefore, the 
delivery of stem cell secretome is expected to be a prominent approach, since it has potential to 
achieve similar effect without causing safety and ethical problems with cell implantation. Among 
different cells, cardiac fibroblast (CF) is the largest cell population in the heart, and its secretome 
has been shown to protect cardiomyocytes under hypoxia. Thus, the objective of this work is to 
deliver CF secretome to the heart after MI. In the first part of this thesis, CF secretome was 
optimized in vitro by adjusting environmental oxygen condition and substrate stiffness. We found 
that the secretome collected under hypoxic condition (1% O2) and soft substrate (6 kPa) can most 
effectively boost the survival of endothelial cells and cardiomyocytes under hypoxia. In the second 
 viii 
part, we developed platelet-membrane coated nanoparticles as a delivery vehicle for CF secretome. 
The nanoparticles had the capability of sustainedly releasing various growth factors such as PDGF, 






















Chapter 1 Introduction 
1.1 Myocardial infarction  
 Myocardial infarction (MI) is the one of main causes of death worldwide. Over one 
million deaths due to MI are reported in the United State every year [1]. MI causes irreversible 
damage to the heart because of decreasing blood flow and lack of oxygen supply [2]. Currently, 
there are several kinds of treatment for MI. Patients can directly take drugs to break up blood clot 
or dissolve arterial blockage, such as aspirin and tissue plasminogen activator [2]. Also, some 
drugs can be injected in the blood to treat. Moreover, the angioplasty can be performed to open 
narrowed blood vessel and let blood flow easily [3]. To redirect blood flow around the blocked 
blood vessels, the coronary bypass surgery may be performed [4]. Furthermore, some electronic 
medical devices, such as pacemakers, can be implanted in the infarcted heart to keep regular beat 
[2]. For patients with end-stage heart failure, a heart transplantation may be required [2].  
 After MI, the loss of cardiomyocytes and formation of scar tissues are irreversible, 
leading to decreased cardiac function [5]. Thus, it is important to replace the injured cells. 
However, the existing surgical treatments are unable to promote the generation of new cardiac 
tissue. The application of stem cells can be a promising therapeutic option [6].  
1.2 Stem cell therapy to treat MI 
 The use of stem cells to treat MI is expected by their two conspicuous capacities of self-
renewal and differentiation into tissues [7]. In order to achieve the goal of regenerating the 
damaged tissues, the stem cell should be able to differentiate into cardiac lineages, such as 
myocytes and vascular endothelial cells [6]. The primary types of stem cells used in treatments for 
myocardial infarction are embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), 
bone marrow mononuclear cells (BMMNCs), and mesenchymal stem cells (MSCs) [6]. Among 
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these stem cells, both ESCs and iPSCs are pluripotent and able to differentiate into all cell types, 
but ESCs may lead to ethical and safety concern, and iPSCs have the tumorigenic possibility [8,9]. 
BMMNCs has been shown to enhance left ventricular function, but they can differentiate into 
heterogeneous cell types which may not be advantaged for heart repair [6]. Although MSCs 
perform the immune-privileged ability , its cell retention, engraftment, and survival rate still is 
low [6].  
 Based on the above disadvantages of stem cell therapy, stem cell secretome has emerged 
as a promising therapeutic option. It has been shown that the key element of stem cell therapy 
should be attributed to its paracrine mechanism to promote regeneration [10].  
1.3 Cell secretome  
 Stem cells can affect the surrounding cells by secreting soluble growth factors, cytokines, 
extracellular vesicles, and exosomes, altogether known as secretome [10]. As the part of 
composition of secretome, growth factors play a significant role in heart repair by promoting cell 
proliferation, cytoprotection, and migration. The commonly secreted factors include 
angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), basic fibroblast growth factor (bFGF), platelet-
derived growth factor (PDGF), vascular endothelial growth factor (VEGF), hepatocyte growth 
factor (HGF), tumor necrosis factor alpha (TNF-a), collagens, insulin-like growth factor 1 (IGF-
1), interleukin-1 (IL-1), matrix metalloproteinases (MMPs), transforming growth factor beta 
(TGF-b), tissue inhibitor of metalloproteinases (TIMPs), bone morphogenetic protein 4 (BMP-
4), interleukin-6 (IL-6), interleukin-7 (IL-7), neurotrophin-3 (NT-3), nerve growth factor (NGF), 
glial cell line-derive neurotrophic factor (GDNF), and brain-derived neurotrophic factor (BDNF). 
Among these factors, Ang-1, bFGF, IGF-1, IL-1, PDGF, VEGF, HGF, and TNF-a have been 
shown to be useful to angiogenesis in the heart [10]. Except for angiogenesis, bFGF, HGF, IGF-1, 
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IL-1, and VEGF also have been stated they have specific function in cardioprotection [10]. 
Moreover, several secreted factors can inhibit fibrosis, such as collagens, MMPs, TGF-b, and 
TIMPs [10].  
1.4 Delivery system for cell secretome 
 In order to deliver secretome to the damaged tissues, several approaches have been 
investigated, such as transplantation of artificial cardiac patch encapsulated secreted factors from 
stem cells, injectable and biocompatible hydrogels as carriers of secretome, injectable nanofibers 
bonded with secretome, and biomimetic nanoparticles [11–15]. Huang et al. have developed 
therapeutic cardiac patch to deliver the secreted factors of cardiac stromal cells to rat/porcine 
heart after MI, and they found that the cardiac recovery was supported by reducing scarring and 
improving angiomyogenesis [11]. An injectable hydrogel has been developed by Waters et al to 
deliver secretome secreted by human adipose-derived stem cells to the peri-infarct myocardium, 
leading to decreased scar area and increased cardiac function [12]. Webber et al. have designed a 
factor-loaded injectable nanofiber network and injected into mouse heart after MI, and the 
preservation of haemodynamic function was found by them [13]. Yasin et al have fabricated 
nanoparticles loaded with VEGF to a murine myocardial infarction model, followed by 




Chapter 2 Modulation of Cardiac Fibroblast Secretome in Response to Different 
Environmental Cues 
2.1 Introduction 
 Compared to the disadvantages of stem cells, which are the unlimited cell types 
differentiated from stem cells, the sophisticated extraction procedure, and high cost, the 
advantage of cardiac fibroblasts (CFs) is prominent. CFs has been defined as the main effector to 
prevent heart rupture by secreting factors in the infarcted heart [17]. Moreover, the large number 
of CFs is easier to obtain compared to stem cells. Furthermore, the largest cell numbers in the 
heart are cardiac fibroblasts, which has been shown to be conductive to mechanical, structural, 
and biochemical properties of the heart [18]. Compared to other stem cells, CFs are the host cells 
obtained the natural advantages. CFs also have been stated to be able to secrete a large number of 
growth factors used in treatments for MI, such as VEGF, PDGF, bFGF, TNF-a, and IL-1b [19]. 
Furthermore, the secreted factors from CFs can protect cardiomyocytes from hypoxic condition, 
induced hypertrophy, and ischemia injury [20]. 
2.2 Materials and methods 
2.2.1 Materials 
Acrylamide and N,N′-methylenebisacrylamide were purchased from Sigma-Aldrich. 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) and ammonium persulfate (APS) were 
purchased from Bio-rad. Isopropanol was purchased form Fisher Scientific. Collagen type I was 
obtained from Corning. Hydrophobic glass slides were purchased from Bio-rad. TRI Reagent 
was purchased from Sigma. Acid phenol:CHCl3 was purchased from Ambion. Nuclease-free 
water and SYBR Green were purchased from Thermo Scientific. High-capacity cDNA reverse 
transcription kit was purchased from Thermo Fisher Scientific. 
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2.2.2 RCF culture 
 Rat cardiac fibroblasts (RCFs) were cultured and seeded in a T75 flask with 10 mL 
culture medium consisting of Dulbecco’s modified Eagle medium (DMEM), 12% fetal bovine 
serum (FBS), and 1% penicillin/streptomycin under normal culture conditions (21% O2, 5% 
CO2, 37°C). The culture medium was changed every two days and RCFs were passaged when 
90% confluency was reached. 
After 90% confluency was reached, RCFs were digested using 0.25% trypsin/EDTA for 5 
mins at 37℃ and centrifuged at 1600 rpm for 7 min. Collected cells were seeded in 100-mm 
dishes supplemented with culture medium consisting of DMEM, 12% FBS, and 1% penicillin. 
The cells were maintained under normal culture conditions (21% O2, 5% CO2, 37°C) overnight. 
The medium was then replaced with serum-free medium. One dish was incubated under hypoxic 
condition (1% O2, 5% CO2, 37°C) for 24 hours. One dish was incubated under 5% O2 and 5% 
CO2 at 37°C for 24 hours. One dish was incubated under normal culture condition (21% O2, 5% 
CO2, 37°C) for 24 hours. After incubation, the media was aspirated, and the cells were lysed 
using 1 mL of TRI reagent and then transferred into a 1.7 mL centrifuge tube to store at -80℃ 
for further experiments. 
2.2.3 PAM gel fabrication and characterization  
 Acrylamide, bis-acrylamide, and APS were dissolved in deionized (DI) water to form 
solutions with concentration of 40% w/v, 2% w/v, and 10% w/v, respectively. Polyacrylamide 
(PAM) gel solution was prepared by mixing 40% w/v acrylamide solution, 2% w/v bis-
acrylamide solution, and DI water at 4 different ratios [21]. The ratio of these reagents and the 
abbreviation of the corresponding gel were specified in Table 1. 5mL of polyacrylamide gel 
solution was placed into a 50-mL tube. 25 μL of 10% w/v APS and 2.5 μL of TEMED were 
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added into the same tube to achieve final concentration of 0.05% and 0.5%, respectively. The 
solution was gently mixed by pipetting up and down 10 – 15 times. The gel solution was pipetted 
onto the 0.75 mm space which was hold by two hydrophobic glass slides. 500 μL of isopropanol 
was pipetted above the gel solution to remove bubbles. After 1 hour, the PAM gel was peeled off 
carefully. To obtain a desired shape which was similar to the plate well of a 6-well plate, the cap 
of a 50-mL tube was used to cut PAM gels to circles. One PAM gel was placed in each well by 
forceps. 
 To determine PAM gels stiffness, the storage modulus was measured by rheometer. The 
Young’s modulus, E was related to storage modulus by using the equation: 𝐸 = 𝐺!2(1 + 𝑣), 
where 𝑣, the Poisson ratio was approximated to 0.5 for PAM gel [22].  
2.2.4 Collagen coating of PAM gels 
Before coating, the 6-well plate was placed under an UV lamp for 1 hour while all PAM 
gels were soaked in 1x phosphate buffered saline (PBS) to keep hydrated. 0.2 mg/mL collagen 
solution was prepared by diluting the 3.78 mg/mL collagen type I solution in PBS. 500 μL of 
diluted collagen solution was pipetted into each well to completely cover the gel surface. The 
plate was covered by parafilm and placed at 4℃ overnight to allow collagen coating. After 
aspirating collagen solution and rinsing with PBS to remove excess collagen solution, the plate 
was placed in a biosafety cabinet under UV to sterilize for 1 hour.  
2.2.5 Immunocytochemical staining 
  RCFs were cultured and seeded on PAM gels in 6-well plate with 2 mL culture medium 
consisting of DMEM without serum at a hypoxia incubator (1% O2, 5%CO2, 37°C) overnight. 
RCFs were fixed with 500 μL of 4% paraformaldehyde (PFA) solution. After fixation for 50 
mins, blocking buffer was added to each well and incubated for 1 hour. Then, the fixed cells 
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were incubated with mouse anti-alpha smooth actin-alpha (α-SMA, Abcam) at 4 C overnight. 
Goat anti-mouse Alexa Fluor 647 (Invitrogen) was used as a secondary antibody to stain the cells 
at room temperature for 1 hour. Nuclei and cytoplasm were stained with DAPI (Sigma) and F-
actin (Invitrogen), respectively. Fluorescent images were taken using a confocal microscope 
(Olympus FV1200). 
2.2.6 RCF secretome collection 
 After 90% confluency was reached, RCFs were digested using 0.25% trypsin/EDTA for 5 
mins at 37℃. Collected cells were seeded onto the PAM gels supplemented with culture medium 
consisting of DMEM, 12% FBS, and 1% penicillin. The cells were left to settle under normal 
culture conditions (21% O2, 5% CO2, 37°C) overnight. The medium was then replaced with 
serum-free medium, and the plate was incubated under hypoxic condition (1% O2, 5% CO2, 
37 °C) for 24 hours. The medium of each PAM gel was collected, filtered by 0.22 μm filter, and 
stored at –80°C for further experiments. The secretomes collected on 4 PAM gels with different 
stiffness were named as PAM1, PAM2, PAM3, PAM4, respectively. The remaining cells were 
collected for mRNA collection. 
2.2.7 mRNA collection and concentration measurement 
 Cells from RCF secretome collection were lysed using 1 mL of TRI reagent and then 
transferred into a 1.7 mL centrifuge tube to incubate at room temperature for 5 mins. 150 μL 
phenol/CHCl3 was added to mixture until it became cloudy. The tube was vortexed for 20 
seconds and then incubated at room temperature for 10 mins, followed by centrifugation at 
12,000 g, 4℃ for 15 mins. After centrifugation, the upper transparent RNA-rich layer was 
collected in a new 1.7 mL centrifuge tube, following by adding 150 μL isopropanol. The tube 
was vortexed for 20 seconds and then incubated at room temperature for 15 mins. The tube was 
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centrifuged at 12,000 g, 4°C for 10 mins. After centrifugation, the supernatant was removed, 
followed by adding 150 μL of 75% ethanol (in DEPC water). The tube was vortexed for 20 
seconds and centrifuged at 12,000 g, 4°C for 5 mins. After centrifugation, the supernatant was 
removed. The open capped tube was placed in the biosafety cabinet for 20 mins to air-dry. 22 μL 
nuclease free water was added to dissolve the remaining RNA. RNA concentration was 
measured by NanoDrop (ND-1000 Spectrophotometer) for cDNA synthesis. 
2.2.8 cDNA synthesis 
 Complementary DNA (cDNA) was synthesized at 1000 ng/reaction using a high capacity 
cDNA reverse transcription kit (Thermo Fisher) by Mastercycler (Eppendorf). The synthesized 
cDNA was stored at – 20°C for Real-time RT-PCR.  
2.2.9 Real-time RT-PCR 
 As described at cDNA Synthesis, cDNA was obtained. SYBR green (Invitrogen) and 
selected primer pairs (Table 2) were mixed to perform real-time RT-PCR. β-actin was served as 
a housekeeping gene.  Fold of increase was calculated using ΔΔCt method. 
2.2.10 Sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE)  
 Protein concentration was measured using Bradford protein assay. 
Mini-protean TGX stain-free precast gel (Bio-rad) was used to load proteins. 20 ug protein was 
loaded in each lane. The running buffer for SDS-PAGE was 25 mM Tris, 190 mM glycine and 
0.1% SDS. The voltage was kept at 30 V for 15 min and 80 V for 1 hour. The images of the gel 
were obtained by Chemi-Doc XRS+ system (Bio-rad) 
 9 
2.2.11 Enzyme-linked immunosorbent assay (ELISA) 
 100 µL diluted capture antibody was added to each well of a 96-well plate, followed by 
sealing with parafilm and incubating overnight at room temperature. The remaining liquid was 
aspirated, following by washing with wash buffer (0.05% Tween-20 in PBS) for 4 times. After 
that, 300 µL block buffer (1% bovine serum albumin in PBS) was added to each well and 
incubated for 1 hour at room temperature. Then, liquids were aspirated, and the plate was washed 
with wash buffer for 4 times. Serial diluted standard protein and release media were added to the 
plate with replicate number of 3, followed by incubating at 4℃ overnight. Then, the remaining 
liquid was aspirated, followed by washing with wash buffer for 4 times. Diluted detection 
antibody was added to each well and incubated for 2 hours at room temperature. After that, the 
liquids were aspirated and followed by washing with wash buffer for 4 times. Diluted Avidin-
HRP conjugate was added to each well and incubated for 30 min at room temperature. Then, the 
liquids were aspirated and followed by washing with wash buffer for 4 times. ABTS liquid 
substrate solution was added to each well and incubated at room temperature in the dark. The 
color development was monitored by a plate reader at 405 nm with wavelength correction at 650 
nm. 
2.2.12 HUVEC culture 
 Human umbilical vein endothelial cells (HUVECs) were cultured and seeded in a T75 
flask supplemented with 10 mL culture medium consisting of EBM and EGM-2 SingleQuots 
(Lonza) under normal culture conditions (21% O2, 5% CO2, 37°C). The culture medium was 
changed every two days and HUVECs were passaged when 90% confluence was reached. 
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2.2.13 HUVEC survival (MTT assay) 
 As previously described at RCF secretome collection, the medium of each PAM gel was 
collected. The medium of PAM2 and EBM without serum were blended at a ratio of 1:1 at a T25 
flask, following by being incubated under hypoxic condition (1% O2, 5% CO2, 37°C) for over 24 
hours to allow gas balance. The medium of PAM4 and EBM without serum were blended at a 
ratio of 1:1 at a T25 flask, following by being incubated under hypoxic condition (1% O2, 5% 
CO2, 37°C) for over 24 hours. All media used in this experiment was stored at hypoxic incubator 
(1% O2, 5% CO2, 37°C) for future experiments. Also, EBM without serum was placed to a T25 
flask and incubated under hypoxic condition (1% O2, 5%CO2, 37 °C) for over 24 hours, named 
as Control medium stored at hypoxic incubator (1% O2, 5% CO2, 37°C) for further experiments. 
 HUVECs were cultured and seeded in two 96-well plates (concentration of 30,000 
cells/mL) with replicate number of 10 for each group supplemented with 200 µL culture 
medium. The cells were maintained under normal culture conditions (21% O2, 5% CO2, 37°C) 
overnight. Without changing culture medium, two plates were transferred to hypoxic incubator 
(1% O2, 5% CO2, 37°C) and incubated. At day 0 and day 4, cell viability was measured for 
control group, PAM2 group (secretome collected on PAM2 gel blended with EBM) and PAM4 
group (secretome collected on PAM4 gel blended with EBM) using MTT assay. Briefly, 20 µL 5 
mg/mL MTT solution was added to each well to incubate for 4 hours. After that, the medium 
was removed carefully and 200 µL DMSO was added to each well, following by shaking for 10 
mins to dissolve all solids at bottom and reading the absorbance at 560 nm by a plate reader, and 
substracting background at 670 nm.   
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2.2.14 HUVEC migration 
 HUVECs were cultured and seeded in a 24-well plate (concentration of 175,000 
cells/mL) with replicate number of 4 for each group supplemented with 800 μL culture medium. 
The cells were left to settle under normal culture conditions (21% O2, 5% CO2, 37°C). After 
~90% confluency was reached, the cell monolayer was scratched using a pipette tip, and the cells 
were treated with EBM medium (control group) and secretome collected on PAM2 gel blended 
with EBM (PAM2 group). At 0, 15, 24, and 40 hours, cell migration was quantified by taking 
images with an optical microscope (Olympus IX70). 
2.2.15 HUVEC tube formation 
Three-dimensional collagen gel solution was prepared by mixing 3.78 mg/mL collagen 
type I solution, 5x DMEM, 1x DMEM, and FBS and adjusting pH to 7.3 by adding 1 M NaOH, 
followed by pipetting up and down 10 times. 500 µL solution was added to each well of a 48-
well plate with replicate number of 2 for each group. After 1-hour incubation, the remaining 
liquid was aspirated, following by washing with PBS for 2 times.  
 HUVECs were seeded in collagen gels (concentration of 50,000 cells/mL) supplemented 
with 400 µL culture medium. The cells were left to settle under normal culture conditions (21% 
O2, 5% CO2, 37°C) for 24 hours. The cells were treated with EBM medium (control group) and 
secretome collected on PAM2 gel blended with EBM (PAM2 group). After 24-hour incubation, 
the medium was aspirated, following by washing with PBS. HUVECs were fixed using 4% PFA 
for 50 min, followed by washing with PBS for 4 times. After that, cells were blocked using 
blocking buffer for 40 min, followed by washing with PBS. The diluted F-actin and DAPI were 
used to stain cells for 1 hour, followed by washing with PBS for 5 times. Fluorescent images 
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were taken for each collagen gel using Olympus FV1200 confocal microscope. The tube density 
was quantified from large lumens.  
2.2.16 Cardiomyocyte culture 
 Rat neonatal cardiomyocytes were purchased from Lonza and cultured per 
manufacturer’s instruction. Briefly, the cells were seeded in nitrocellulose-coated plates with rat 
cardiomyocyte growth media (rCGM, Lonza). Bromodeoxyuridine was added to the culture 
media to suppress fibroblast formation. 
2.2.17 Cardiomyocyte survival (MTT assay) 
 Cardiomyocytes were seeded in two 96-well plates (concentration of 10,000 cells/mL) 
with replicate number of 5 for each group supplemented with 200 µL culture medium. At day 0 
and day 2, cell viability was measured for control group, PAM2 group (secretome collected on 
PAM2 gel blended with EBM) and PAM4 group (secretome collected on PAM4 gel blended 
with EBM) using MTT assay. Briefly, 20 µL 5 mg/mL MTT solution was added to each well to 
incubate for 4 hours. After that, the medium was removed carefully and 200 µL DMSO was 
added to each well, following by shaking for 10 mins to dissolve all solids at bottom and reading 
the absorbance at 560 nm by a plate reader, and substracting background at 670 nm.   
2.2.18 Statistical analysis  
 All data were presented as mean ± standard deviation. One-way ANOVA was used to 
analyze the significant difference between experimental groups. The significant difference was 
defined as p < 0.05.  
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2.3 Results and Discussion 
2.3.1 Gene expression of RCF secretome in response to oxygen content 
 To investigate how the RCF secretome changed in response to environmental oxygen 
content, the growth factor expressions were quantified at the mRNA level under 1% O2, 5% O2, 
and 21% O2 culture conditions. RCF secretome under 1% O2 exhibited significantly higher 
Vascular endothelial growth factor (VEGF) expression than 5% O2 (p<0.0001) and 21% O2 
(p<0.0001) (Figure 1a). Besides VEGF, the 1% O2 group had significantly lower interleukin 
(IL1β) expression (p<0.05) and transforming growth factor β (TGFβ) expression (p<0.001) than 
21% O2, whereas 1% O2 and 5% O2 had similar expressions (p>0.05) (Figure 1b, 1c). 
 VEGF is one of the most effective proangiogenic factors [23]. It also plays a crucial role in 
promoting the formation of new blood vessels in the heart with myocardial infarction or other 
ischemic heart diseases [16]. Thus, the significantly higher VEGF expression was the advantage 
of 1% O2 group compared to other groups. Moreover, suppression of IL1β has been proven to be 
a treatment in myocardial infarction [24]. It has been shown that the expression of genes which are 
essential to the regulation of calcium homeostasis are reduced by IL1β [25]. The expression of 
nitric oxide synthase in cardiac myocytes is promoted by IL1β [26]. In addition, TGFβ has been 
proven to induce myocardial infarction and activate fibrosis in the infarcted heart [27]. Therefore, 
the lower expression of IL1β and TGFβ was another advantage of 1% O2 group compared to 
other groups. The above results reveal that the lower environmental oxygen content significantly 
optimized RCF secretome. Hypoxic culture condition (1% O2, 5% CO2, 37°C) was chosen for 
further experiments. 
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2.3.2 PAM Gel Fabrication and Characterization 
 PAM gels were fabricated with four different concentrations of acrylamide and 
crosslinker bis-acrylamide and cut to circles (Figure 2a). To determine PAM gels stiffness, the 
storage modulus was measured by using rheometer (Table 3). The Young’s modulus, E was 
related to storage modulus by using the equation: 𝐸 = 𝐺!2(1 + 𝑣), where 𝑣, the Passion ratio 
was approximated to 0.5 for PAM gels [22]. For PAM1 which contained 5% acrylamide and 0.1% 
crosslinker bis-acrylamide, its storage modulus was 0.43 ± 0.02 kPa and Young’s modulus was 
1.29 ± 0.05 kPa. For PAM2 which contained 8% acrylamide and 0.1% crosslinker bis-
acrylamide, its storage modulus was 2.04 ± 0.10 kPa and Young’s modulus was 6.11 ± 0.31 kPa. 
For PAM3 which contained 8% acrylamide and 0.25% crosslinker bis-acrylamide, its storage 
modulus was 4.82 ± 0.09 kPa and Young’s modulus was 14.46 ± 0.27 kPa. For PAM4 which 
contained 12% acrylamide and 0.25% crosslinker bis-acrylamide, its storage modulus was 10.83 
± 0.10 kPa and Young’s modulus was 32.50 ± 0.31 kPa (Figure 2b). These results confirmed that 
the stiffness of PAM gel was controllable by adjusting the concentration of acrylamide or 
crosslinker (bisacrylamide) concentration. We found that higher acrylamide or crosslinker 
(bisacrylamide) concentration resulted in stiffer PAM gel. 
To determine RCF morphology and the tendency to differentiate into myofibroblasts, 
immunocytochemical staining of SMA was performed, and the fluorescent images were taken 
for RCF on PAM1 to 4 and normal culture plate (Figure 3). α-SMA is regarded as a marker for 
myofibroblasts [28]. With the increase of stiffness, the α-SMA expression increased and the RCFs 
were observed to differentiate into myofibroblasts. The above results demonstrate that the 
stiffness of PAM gel could affect the α-SMA expression. Higher stiffness of PAM gel could lead 
to more α-SMA expression. RCFs would differentiate into myofibroblasts on a stiffer substrate.   
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Fibroblasts has been shown to proliferate, migrate, and regulate cardiac extracellular 
matrix (ECM), leading to sustain cardiac homeostasis [29]. Myofibroblasts are differentiated from 
fibroblasts, which are unusually present in the healthy myocardium, but normal in the infract 
scar, leading to fibrogenesis [30]. The activeness of myofibroblasts in healthy area of the heart can 
lead to fibrosis and adverse myocardial remodeling [31]. Myocardial remodeling (REM) is a 
detrimental process of changing in the heart’s size and shape, being caused by myocardial 
infarction [32]. High myofibroblast density in the remote myocardium results in increased 
myocardial stiffness, leading to systolic and diastolic dysfunction and heart failure [29]. 
Moreover, compared to the proven myocyte  hypertrophy caused by secretome activated 
myofibroblasts, secretome of CFs has been performed to protect cardiomyocytes from induced 
hypertrophy [20,33]. Therefore, the PAM gel with less α-SMA expression performed greater than 
others.  
2.3.3 Effects of PAM gels on RCF secretome under hypoxic condition 
 To investigate how the stiffness of PAM gels affects RCF secretome under hypoxic 
condition, the total amounts of protein in RCF cultured on PAM1 to 4 were measured by running 
SDS-PAGE (Figure 4). Compared to other three groups, the PAM2 groups expressed apparently 
much greater amount of protein.  
 To determine how RCF paracrine effects were expressed on PAM gels under hypoxic 
condition, the growth factor expressions were quantified at the RNA level. For basic fibroblast 
growth factor (bFGF), the PAM2 group exhibited significantly higher than PAM3 group 
(p<0.05) and PAM4 group (0.01) (Figure 5a). For platelet-derived growth factor (PDGF), the 
PAM2 group also performed significantly higher than PAM3 group (p<0.01) and PAM4 group 
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(p<0.0001) (Figure 5b). For VEGF, the PAM2 group also performed significantly higher than 
PAM3 group (p<0.05) (Figure 5c).  
bFGF has been shown to be a protective role in myocardial infarction and hypoxia 
cardiomyocytes [34]. Also, bFGF can promote cardiac stem cell migration, reduce infarct size, 
and enhance cardiac systolic function [35,36]. Moreover, it has been shown that PDGF is one of the 
growth factors which can promote cell growth, differentiation, proliferation, and migration, 
leading to stimulate angiogenesis [37]. The importance of VEGF in myocardial infarction has 
been discussed before. Thus, the significantly higher expressions of PDGF, VEGF, and bFGF 
were the advantage of PAM2 group compared to other three groups. The above results 
demonstrate that PAM2 gel optimized RCF secretome under hypoxic condition.  
 To determine the concentration of bFGF of RCF secretome collected on PAM1 to 3 
under hypoxia, ELISA was used to measure. The PAM2 gel significantly increased the 
concentration of bFGF in RCF secretome compared to PAM1 (p<0.01) and PAM3 (p<0.01) 
(Figure 6). These results demonstrate that PAM2 significantly enhanced the amount of bFGF in 
RCF secretome under hypoxia.  
 Therefore, based on the above results, PAM2 group was chosen for further experiments. 
2.3.4 Effects of RCF secretome on HUVEC survival, migration and tube formation under 
hypoxic condition 
Endothelial cells play a pivotal role in angiogenesis, which is a crucial process after 
myocardial infarction. The survival, migration and fusion of endothelial cells is the prerequisite 
for formation of new blood vessels [38].  
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To investigate whether the PAM2 can increase HUVEC survival under hypoxic 
condition, HUVECs were cultured using three different culture media. Control group was used 
with serum-free medium; PAM2 group was used with serum-free medium and PAM2 medium at 
ratio of 1:1; PAM4 group was used with serum-free medium and PAM4 medium at ratio of 1:1. 
Although the cell viability of all three groups at day 4 decreased compared to day 0, the cell 
number of PAM2 group was significantly higher than control group (p<0.0001) and PAM4 
group (p<0.01) (Figure 7). Moreover, there was no significant difference between control group 
and PAM4 group (p>0.05). The in vitro results reveal that the secretome collected on low 
stiffness promoted HUVEC survival under hypoxic condition, but the secretome collected on 
high stiffness did not have much greater effect than serum-free medium. Thus, PAM2 medium 
was used for further experiment. 
 To determine whether the RCF secretome collected on PAM2 enhanced HUVEC 
migration, the migration ratio of two groups (Control and PAM2) was statistically measured 
based on images taken at 0, 15, 24, and 40 hours (Figure 8a). For control group, the migration 
ratios at 15, 24, and 40 hours were lower than 20%. For PAM2 group, the migration ratios at 15, 
24, and 40 hours were persistently increasing. At these three time spots, PAM2 group had 
significantly greater migration ratios than control group (p<0.0001) (Figure 8b).  
 To investigate whether the RCF secretome collected on PAM2 promoted HUVEC tube 
formation, the normalized tube density of two groups was statistically measured based on 
fluorescent images taken after 24-hour incubation (Figure 9a). For the number of cells, PAM2 
group performed apparently much greater than control group. Besides the number of cells, 
PAM2 group had significantly greater tube density than control group (p<0.001) (Figure 9b). 
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The above results reveal that the RCF secretome collected on PAM2 played an essential role on 
HUVEC survival, migration, and tube formation. 
2.3.5 Effect of RCF secretome on cardiomyocytes survival under hypoxic condition 
To investigate whether the PAM2 can increase cardiomyocytes survival under hypoxic 
condition, cardiomyocytes were cultured using three different culture media. Control group was 
used with serum-free medium; PAM2 group was used with serum-free medium and PAM2 
medium at ratio of 1:1; PAM4 group was used with serum-free medium and PAM4 medium at 
ratio of 1:1. Although the cell viability of all three groups at day 2 decreased compared to day 0, 
the cell number of PAM2 group were significantly higher than control group (p<0.01) and 
PAM4 group (p<0.001) (Figure 10). Moreover, there was no significant difference between 
control group and PAM4 group (p>0.05). The in vitro results reveal that the secretome collected 
on low stiffness protected cardiomyocytes under hypoxic condition, but the secretome collected 
on high stiffness did not have greater effect than serum-free medium.  
2.4 Conclusion 
 In this work, RCF secretome was modulated in response to different environmental 
oxygen contents and stiffness. Under hypoxic culture condition (1% O2, 5% CO2, 37°C), the 
RCF secretome collected on PAM2 gel exhibited greater secretion of growth factors cytokines at 
both RNA and protein level. Higher cell survival ratio, migration ratio, and tube formation ratio 
confirmed the useful treatment of optimized RCF secretome. This modulation of cardiac 
fibroblast secretome may promote heart repair after myocardial infarction. 
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Chapter 3 Targeted Delivery of Platelet Membrane Coated PLGA Nanoparticles with 
Sustained Cardiac Fibroblast Secretome Release 
3.1 Intro  
 Among the current delivery methods, such as injectable hydrogel and transplantation of 
patch, they are limited by indirect delivery with a surgery to open chest, leading to high risk to 
break myocardium [39]. In addition, nanoparticle delivery system is a minimally-invasive method 
by intravenous injection, and its size is small enough to circulate in the blood stream [40]. To 
overcome the limitations of nanoparticle, such as short retention and potential immune rejection, 
a cell-membrane coated nanoparticle delivery system has been designed [41]. Among various cell 
membranes, platelet membrane coating has advantage of avoiding immune rejection, capability 
of ligand binding and selectively binding to injured endothelium by nature. The objective of this 
work is to coat platelet membrane with nanoparticles to targeted bind to the injured endothelium 
[42]. 
3.2 Materials and methods 
3.2.1 Materials 
 Poly (lactide-co-glycolic acid) (PLGA, LACTEL) with a LA/GA ratio of 50/50 was 
purchased from Lactel Absorbable Polymers. 
3.2.2 Secretome collection  
As described at RCF secretome collection, the medium of PAM2 was collected, filtered 
by 0.22 μm filter, and freeze-dried. The powder was dissolved in 2 mL DI water, and 
concentrated using vivaspin 500 concentrator (MWCO=3kDa) to obtain a desalted secretome 
solution for nanoparticle fabrication. 
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3.2.3 Nanoparticle fabrication and characterization 
 100 mg PLGA was weighed and dissolved in 2 mL dichloromethane (DCM). 200 µL 
secretome solution was emulsified with PLGA solution using an ultrasonicator for 1 min to 
obtain a homogeneous and opaque solution. The solution was quickly transferred into a beaker 
with 8 mL of 1% w/v polyvinyl alcohol (PVA) water solution, following by 1-minute 
ultrasonication. After that, the beaker was placed on a magnetic stirring plate with a moderate 
stirring speed at room temperature overnight to evaporate solvent. The remaining solution was 
transferred into a 50-mL tube, following by adding DI water to 35 mL and centrifuging at speed 
of 12,000 rpm for 15 mins. After centrifugation, the supernatant was removed carefully. The 
centrifugation/resuspension process was repeated for 4 times to remove PVA. After that, the 
washed nanoparticles were freeze-dried, collected, and stored at -80℃ for further experiments.  
 The size distribution of nanoparticles was measured by dynamic light scattering at room 
temperature. The samples were prepared by diluting nanoparticles with DI water and filtering 
with a 0.45 µm membrane filter. 
3.2.4 Growth factor release characterization 
 75 mg of fabricated nanoparticles was weighed and suspended in 5 mL PBS with 1% 
penicillin to achieve a final concentration of 15 mg/mL. The suspension was evenly separated 
into twelve 1.7-mL centrifuge tube and incubated in a 37℃ water bath for release. At day 1, 2, 3, 
5, 7, 10, and 14, the release media were collected and stored at -80℃ for further experiments.  
 The concentration of growth factor was measured by ELISA [43,44]. 100 µL diluted 
capture antibody was added to each well of a 96-well plate, followed by sealing with parafilm 
and incubating overnight at room temperature. The remaining liquid was aspirated, followed by 
washing with wash buffer (0.05% Tween-20 in PBS) for 4 times. After that, 300 µL block buffer 
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(1% Bovine Serum Albumin in PBS) was added to each well and incubated for 1 hour at room 
temperature. Then, liquids were aspirated, and the plate was washed with wash buffer for 4 
times. Serial diluted standard and release media were added to the plate with replicate number of 
3, followed by incubating at 4℃ overnight. Then, the remaining liquid was aspirated, followed 
by washing with wash buffer for 4 times. Diluted detection antibody was added to each well and 
incubated for 2 hours at room temperature. After that, the liquids were aspirated and followed by 
washing with wash buffer for 4 times. Diluted Avidin-HRP conjugate was added to each well 
and incubated for 30 mins at room temperature. Then, the liquids were aspirated and followed by 
washing with wash buffer for 4 times. ABTS liquid substrate solution was added to each well 
and incubated at room temperature in the dark. The color development was monitored by a plate 
reader at 405 nm with wavelength correction set at 650 nm. 
3.2.5 Platelet membrane coating and characterization 
The platelet rich plasma was extracted from bovine blood. Three freeze-thaw processes 
were conducted on the platelets in a 1.7-mL centrifuge tube to break the cell membrane. After 
the final thaw process, the tube was centrifuged at 4,500 g for 5 min at room temperature. Then, 
the pelleted platelet membrane was washed with PBS containing protease inhibitor for 3 times. 
After sonication for 5 min, 2 mg freeze-dried nanoparticles were added into 2 mL platelet 
membrane solution, following by sonicating for 5 mins. The platelet membrane coated (PLM-
coated) nanoparticles were stored at 4℃ for further experiments. 
 The size distribution of platelet membrane coated nanoparticles was measured by 
dynamic light scattering at room temperature. The samples were prepared by diluting 
nanoparticles with DI water and filtering with a 0.45 µm membrane filter. 
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3.2.6 Cell uptake  
 As described at Platelet membrane coating and characterization, PLM-coated 
nanoparticles were obtained. Ischemia-targeting peptide CSTSMLKAC (CST) in NaH2PO4 
buffer was mixed with PLM-coated nanoparticles, following by adding suberic acid bis(N-
hydroxysuccinimide ester) dissolved in DMSO and stirring at room temperature for 2 hours. 
After adding glycine and dialyzing against DI water overnight, CST conjugation was finished. 
 Glass slides were placed in a 24-well plate, coated with collagen, and incubated for 1 
hour at room temperature. After the remaining liquids were aspirated, the plate was placed in a 
biosafety cabinet under UV to sterilize for 1 hour. HUVECs and RCFs were cultured and seeded 
in the glass slides (concentration of 50000 cells/mL) with replicate number of 2 for each kind of 
cells supplemented with 800 μL culture medium. The cells were left to settle under normal 
culture conditions (21% O2, 5% CO2, 37°C). After 24-hour incubation, the medium was replaced 
with 1 mg/mL diluted, conjugated PLM-coated nanoparticles with normal medium. After 24-
hour incubation, the medium was aspirated, following by washing with PBS. HUVECs and 
RCFs were fixed using 4% PFA for 50 mins, following by washing with PBS for 4 times. After 
that, cells were blocked using blocking buffer for 40 mins, following by washing with PBS. The 
diluted F-actin and DAPI were used to stain cells for 1 hour, following by washing with PBS for 
5 times. Fluorescent images were taken for each glass slide using Olympus FV1200 confocal 
microscope. The ratios of cell uptake were quantified by measuring the number of cells which 
have nanoparticles inside divided by total number of cells. 
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3.2.6 Statistical analysis  
 All data were presented as mean ± standard deviation. One-way ANOVA was used to 
analyze the significant difference between experimental groups. The significant difference was 
defined as p < 0.05. 
3.3 Results and Discussion 
3.3.1 Fabrication and characterization of PLGA nanoparticles 
 The PLGA nanoparticles were fabricated by the method of double emulsion to form core-
shell structure with PLGA as shell and RCF secretome as core. The size of uncoated PLGA 
nanoparticles was 218.33 nm with a PDI of 0.17, while the size of PLM-coated PLGA 
nanoparticles was 239.80 with a PDI of 0.04 (Figure 11a). The results demonstrate that the size 
of nanoparticles increased after coating with platelet membrane (Table 3). The size of PLGA 
nanoparticles did not change significantly within 30-day incubation in PBS at 37ºC (Figure 11b). 
The above results reveal that the PLGA nanoparticles were stable in physiological environment. 
3.3.2 Growth factor release kinetics  
 To determine how different growth factors released from the nanoparticles, the 
concentrations of PDGF, VEGF, and bFGF in release media were measured and calculated by 
performing ELISA (Figure 12). The above results demonstrate that the growth factors were 
sustainedly released by nanoparticles in 37°C over 14 days.  
Herein, among PDGF, VEGF, and bFGF, they all play essential roles in the treatment of 
myocardial infarction. The sustained release delivery system is useful to avoid a consequence 
that the loaded secretome are metabolized and eliminated from the body too fast to achieve the 
desired therapeutic effect [45].  
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3.3.3 Cell uptake for platelet membrane coated nanoparticles 
 To investigate how the platelet membrane affected HUVEC and RCF uptake 
nanoparticle, the ratio of cell uptake was quantified by counting the number of cells endocytosed 
nanoparticles. For both of HUVEC and RCF, the ratios of cell uptake were lower than 15% 
(Figure 13).  
3.4 Conclusion 
 In this work, a RCF secretome release system was designed and fabricated. The RCF 
secretome nanoparticles exhibited sustainedly release RCF secretome and stability in 
physiological environment. This delivery system may have the potential treatment for the heart 










Chapter 4 Future Work 
 The PLM-coated PLGA nanoparticles can sustainedly release the loaded RCF secretome 
which is modulated based on hypoxic culture condition and environmental stiffness. However, 
we still do not know whether the amount of secretome loaded is enough to promote heart repair 
following myocardial infarction. The effect of secretome loaded nanoparticles should be tested 
by further and deeper experiments in vitro and in vivo. Thus, the therapeutic effect of this 
nanoparticles can be exhibited.  
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PAM1 5 0.1 0.625 0.25 4.125 
PAM2 8 0.1 1 0.25 3.75 
PAM3 8 0.25 1 0.625 3.375 
PAM4 12 0.25 1.5 0.625 2.875 
 
Table 2. Primer sequences used in real-time RT-PCR.  
 Forward primer Reverse primer 
VEGF TATCTTCAAGCCGTCCTGTG GATCCGCATGATCTGCATAG 
PDGFBB AAATCGTGGAAGACATGAAC TTCACAAGCACAATGCAC 
TGFβ ATATAGCAACAATTCCTGGC CGTGGAGTACATTATCTTTGC 
bFGF AACTACAGCTCCAAGCAG GTAACACACTTAGAACCAG 





Table 3. PAM gel stiffness measured by rheology.  
Polyacrylamide 
hydrogel 
Storage Modulus G’ ± SD (kPa) 
Young’s Modulus E ± SD 
(kPa) 
PAM1 0.43 ± 0.02 1.29 ± 0.05 
PAM2 2.04 ± 0.10 6.11 ± 0.31 
PAM3 4.82 ± 0.09 14.46 ± 0.27 
PAM4 10.83 ± 0.10 32.50 ± 0.31 
 
Table 4. Size and PDI of uncoated and PLM-coated nanoparticles. 
 Z-average (nm) PDI  
Uncoated nanoparticle 218.33 0.17 






Figure 1. Gene expression of VEGF, IL1β, and TGFβ in RCF under 1% O2, 5% O2, and 21% O2 
culture conditions. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
 
 




Figure 3. Immunocytochemical staining of F-actin (green) and α-SMA (red) of RCF cultured on 
PAM1 to 4 and culture plate. Nuclei were stained with DAPI (blue).  
 




Figure 5. Gene expression of RCF cultured on PAM1 to 4. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 
 
Figure 6. Concentration of bFGF of RCF secretome collected on PAM1 to 3. *p<0.05, 





























Figure 7. In vitro HUVEC survival under hypoxic condition. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 
 
Figure 8. In vitro HUVEC migration under hypoxic condition. scale bar = 200 µm, *p<0.05, 






















Figure 9. In vitro HUVEC tube formation under hypoxic condition with quantification. Nuclei and 































Figure 12. Growth factor release kinetics. The PDGF, bFGF, and VEGF release of the 
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